International Journal of Clinical Research

Objective: To explore the clinical effect and influence of trimetazidine in patients with ischemic cardiomyopathy. Methods: A total of 112 patients with ischemic cardiomyopathy admitted to our hospital from August 2020 to August 2021 were selected as the study subjects. They were divided into two groups according to the principle of systematic randomization: conventional treatment group (control group) and combined treatment group (research group), each of which was divided into 56 cases/group. The control group received conventional treatment according to conventional treatment agents, and the research group received combined treatment with trimetazidine on the basis of conventional treatment methods. The overall therapeutic effect and the changes of relevant body indicators and data were observed in the two groups. Results: Through data comparison and rehabilitation diagnosis, the body index recovery and treatment efficiency of patients in the study group were significantly better than those in the control group (the treatment efficiency of patients in the study group was 96.4%, the treatment efficiency of patients in the control group was 82.1%), the test results showed that the difference was statistically significant (P<0.05). The improvement of cardiac function in the study group was significant, and the improvement of physical function index was better than that in the control group (P<0.05). Conclusion: The combination of conventional drugs and trimetazidine in clinical treatment has obvious effect on the improvement of the condition of patients with ischemic cardiomyopathy, and has high application and promotion value.

Trimetazidine; Ischemic Cardiomyopathy; Clinical Efficacy; Conventional Treatment